More on VERA
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $28.57 |
|
|||
| Open | $28.30 | ||||
| 52 Wk High | $1.18 | ||||
| 52 Wk Low | $0.36 | ||||
| Day High | $28.40 | ||||
| Day Low | $27.50 | ||||
| P/E | 464.67 | ||||
| EPS | $0.06 | ||||
| Volume | 1,294,582 | ||||
- Leerink Starts Vera Therapeutics (VERA) at Market Perform
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics to present ORIGIN 3 trial data at ASN Kidney Week
- Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN
- Form 4 Vera Therapeutics, Inc. For: Sep 15 Filed by: Fordyce Marshall
- TD Cowen Reiterates Buy Rating on Vera Therapeutics (VERA)
- Raymond James Reiterates Strong Buy Rating on Vera Therapeutics (VERA)
- Form 8-K Vera Therapeutics, Inc. For: Sep 15
- Vera Therapeutics drug meets all endpoints in two-year IgAN trial
- Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
Entities mentioned with VERA
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Cowen & Co | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- 13G | View Related Stories »
- Show More...
